Company news

Beijing Foyou Pharma Co., Ltd. news in 2026

Beijing Foyou Pharma Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Initial Repurchase of Shares through Call Auction

November 17, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Holding Unrestricted Shares Concerning Share Repurchase

November 12, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

November 12, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Resolutions of the 9th Meeting of the 3rd Board of Directors

November 9, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Obtaining Drug Registration Certificate for Upadacitinib Sustained-release Tablets

November 6, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Indicative Announcement on Receipt of the Proposal for Share Repurchase from the Chairman

October 28, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Report for Q3 2026

October 27, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Notice on Convening the 1st Extraordinary General Meeting in 2026

October 27, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Resolutions of the 8th Meeting of the 3rd Board of Directors

October 27, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing

October 27, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Appointment of Accounting Firm

October 27, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Addition of Office Address

October 27, 2026

(601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Obtaining Drug Registration Certificate for Rotigotine Patches

October 26, 2026

Announcement on Pledge of Shares Held by Persons Acting in Concert with the Controlling Shareholder

September 1, 2026

Announcement on Obtaining Drug Registration Certificate for Bromocriptine Mesylate Tablets

August 21, 2026

Announcement on the Completion of Raised-Fund Investment Projects

August 14, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

August 11, 2026

Announcement on Obtaining Drug Registration Certificate for Brexpiprazole Orally Disintegrating Tablets

August 7, 2026

Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement

August 3, 2026

Announcement on Obtaining Notice of Approval for Drug Supplementary Application by Subsidiaries

July 16, 2026

Announcement on the Change of Business License of a Controlled Subsidiary

July 13, 2026

Announcement on Inclusion of Products of the Company and Its Subsidiaries in the "National Essential Medicines List (2026 Edition)"

July 10, 2026

Announcement on Obtaining the Drug Supplementary Application Approval Notice for Levothyroxine Sodium Tablets

July 1, 2026

Announcement on Approval Notice of the Supplementary Application for Drugs Obtained for Pinaverium Bromide Tablets

June 24, 2026

Announcement on Obtaining Drug Registration Certificate for Pimecrolimus Cream

June 16, 2026

Announcement on Obtaining Drug Registration Certificate for Methimazole Tablets

June 1, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 26, 2026

Announcement on Obtaining Drug Registration Certificate for Clopidogrel Aspirin Tablets

May 21, 2026

Announcement on Obtaining Drug Registration Certificate for Olmesartan Medoxomil Orally Disintegrating Tablets

May 7, 2026

Report for Q1 2026

April 24, 2026

Announcement on Obtaining Approval for Marketing of Chemical APIs

April 23, 2026

Announcement on Convening the Q1 2026 Performance Briefing

April 21, 2026

Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (I)

April 20, 2026

Announcement on 2025 Annual Profit Distribution Plan

April 13, 2026

Announcement on Obtaining Drug Registration Certificate for Dibutyrosine Adenosyl Methyltransferase Enteric-coated Tablets

April 7, 2026

Announcement on Obtaining the Notice of Approval for Drug Clinical Trials of Bimatoprost Ointment

March 31, 2026

Announcement on Subsidiary's Passing GMP Compliance Inspection

March 30, 2026

Announcement on Obtainment of Drug Registration Certificate for Icosapent Ethyl Soft Capsules

March 23, 2026

Announcement on Obtaining Notice of Approval for Drug Clinical Trials

March 16, 2026

Announcement on Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry

February 11, 2026

Announcement on Obtaining Drug Registration Certificate for Bromhexine Hydrochloride Oral Solution

February 10, 2026

Announcement on Change of the Signing Accountant

January 29, 2026

Announcement on Obtaining Drug Registration Certificate for Trazodone Hydrochloride Tablets

January 23, 2026